RIMS4: A Potential Drug Target and Biomarker for Synaptic Membrane Exocytosis

Target Name: RIMS4

NCBI ID: G140730

RIMS4

RIMS4: A Potential Drug Target and Biomarker for Synaptic Membrane Exocytosis

Synaptic membrane exocytosis (SME) is a critical intracellular transport mechanism that plays a vital role in synaptic plasticity, learning, and memory. The regulation of SME is a complex process that involves multiple interacting proteins. One of the key proteins involved in this process is RIMS4, which is a non-profit RNA-protein scaffold that has been shown to regulate SME in various brain regions.

In this article, we will discuss the role of RIMS4 in SME regulation, its potential as a drug target, and its potential as a biomarker for various neurological disorders.

Role of RIMS4 in SME Regulation

RIMS4 is a 21-kDa protein that is expressed in various brain regions and is involved in the regulation of SME. SME is a critical mechanism for the delivery of neurotransmitters, such as dopamine and synaptolysin, to the postsynaptic target, which is important for the formation and maintenance of synaptic plasticity.

RIMS4 functions as a scaffold protein that can interact with various components of the SME complex. It helps to regulate the level of neurotransmitters at the postsynaptic surface, thereby modulating the strength of synaptic transmission.

Potential as a Drug Target

The regulation of SME by RIMS4 is a promising target for drug development. The neurotransmitter release mechanism is the target of many drugs that are used to treat neurological disorders, such as Parkinson's disease, Alzheimer's disease, and depression.

RIMS4 has been shown to play a role in the regulation of neurotransmitter release by SME. Studies have shown that RIMS4 can interact with the neurotransmitter release factor (NRF), a protein that plays a critical role in the release of neurotransmitters.

In addition, RIMS4 has been shown to interact with the voltage-gated sodium channel (VGSA), which is involved in the regulation of neurotransmitter release. The regulation of neurotransmitter release by RIMS4 and VGSA is a complex process that involves multiple interacting proteins, and further research is needed to fully understand the regulation of SME by these proteins.

Potential as a Biomarker

RIMS4 has also been shown to be a potential biomarker for various neurological disorders. The regulation of SME is a critical process that is involved in the development and progression of many neurological disorders, including Parkinson's disease, Alzheimer's disease, and depression.

Studies have shown that the levels of RIMS4 are altered in the brains of individuals with these disorders. Additionally, the levels of RIMS4 have been shown to be associated with the severity of these disorders.

In conclusion, RIMS4 is a non-profit RNA-protein scaffold that plays a critical role in the regulation of SME. Its regulation of neurotransmitter release is a promising target for drug development, and its potential as a biomarker for various neurological disorders makes it an attractive target for further research.

Protein Name: Regulating Synaptic Membrane Exocytosis 4

Functions: Regulates synaptic membrane exocytosis

The "RIMS4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RIMS4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets